Oregon Pacific Wealth Management LLC Takes $244,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Oregon Pacific Wealth Management LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,075 shares of the medical instruments supplier’s stock, valued at approximately $244,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company in the third quarter worth $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $33,000. Tompkins Financial Corp raised its stake in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC raised its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,844 shares of company stock worth $2,210,716. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.3 %

NYSE BDX opened at $247.63 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $250.91. The stock has a market cap of $71.82 billion, a P/E ratio of 41.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.39. The stock has a 50 day simple moving average of $230.53 and a two-hundred day simple moving average of $233.83.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.42 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.68%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 70.03%.

Analyst Ratings Changes

Several analysts have issued reports on the company. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.